{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:13:39Z","timestamp":1785870819898,"version":"3.56.0"},"reference-count":47,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: In this study, it was aimed to compare transrectal ultrasound (TRUS)- and magnetic resonance imaging (MRI)-derived prostate-specific antigen density (PSAD) in patients with gray-zone PSA levels (4\u201310 ng\/mL), evaluate their diagnostic performance for clinically significant prostate cancer (csPCa), and assess the clinical implications of reclassification across commonly used thresholds. Methods: We retrospectively analyzed 202 men who underwent both TRUS and multiparametric MRI between January 2020 and June 2025. Prostate volume was measured using the ellipsoid formula for TRUS and contour-based planimetry for MRI. PSA density (PSAD) was calculated as total PSA (tPSA, ng\/mL) divided by prostate volume (mL) for each modality: TRUS-PSAD and MRI-PSAD. Agreement between modalities was evaluated using Bland\u2013Altman plots and correlation analyses. Reclassification at PSAD thresholds of 0.15, 0.20, and 0.30 ng\/mL\/mL was assessed using Cohen\u2019s \u03ba and net reclassification improvement (NRI). Diagnostic performance for csPCa (ISUP grade group \u2265 2) was evaluated with ROC analysis and the DeLong test. Inter- and intra-observer reproducibility was determined using intraclass correlation coefficients (ICC) and Cohen\u2019s \u03ba. Clinical utility was assessed by decision curve analysis (DCA). Results: MRI-derived prostate volumes were significantly lower than TRUS-derived volumes (median 47.0 vs. 52.5 mL, p &lt; 0.001), resulting in higher MRI-PSAD values (median 0.14 vs. 0.12 ng\/mL\/mL, p &lt; 0.001). Bland\u2013Altman analysis demonstrated a negative bias for prostate volume (\u22123.2 mL) and a positive bias for PSAD (+0.03). Strong correlations were observed between TRUS and MRI measurements (r = 0.96 for volume and r = 0.94 for PSAD). MRI-PSAD frequently reclassified patients into higher risk categories, yielding positive net reclassification improvement for cancer cases across all thresholds, while introducing some negative reclassification among non-cancer cases. ROC analysis showed comparable overall diagnostic performance between TRUS-PSAD and MRI-PSAD (AUC 0.681 vs. 0.679, p = 0.91). However, MRI-PSAD demonstrated higher sensitivity at predefined thresholds at the expense of reduced specificity, reflecting a threshold-dependent shift rather than improved discrimination. Reproducibility was higher for MRI-derived measurements (ICC = 0.94; \u03ba = 0.83) compared with TRUS (ICC = 0.86; \u03ba = 0.71). Decision curve analysis indicated that MRI-PSAD, particularly when combined with PI-RADS \u2265 3, provided the greatest net clinical benefit at lower threshold probabilities (5\u201315%). Conclusions: MRI-derived PSA density produces systematically higher values than TRUS-based measurements due to inherent differences in prostate volume estimation. While this results in increased sensitivity at standard thresholds, overall discrimination remains unchanged. These findings support the use of modality-specific PSAD thresholds rather than uniform cutoffs across imaging techniques. In clinical practice, MRI-PSAD may provide additional value when interpreted in conjunction with PI-RADS, primarily through improved threshold calibration rather than enhanced diagnostic accuracy.<\/jats:p>","DOI":"10.3390\/curroncol33040221","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:14:46Z","timestamp":1776334486000},"page":"221","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic and Clinical Impact of Imaging Modality on PSA Density: TRUS Versus MRI in Gray-Zone Prostate Cancer"],"prefix":"10.3390","volume":"33","author":[{"given":"Davut Unsal","family":"Capkan","sequence":"first","affiliation":[{"name":"Department of Radiology, Medical Point Hospital, 27060 Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9123-9196","authenticated-orcid":false,"given":"Mehmet","family":"Solakhan","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical Point Hospital, 27060 Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4274\/uob.galenos.2023.2023.6.2","article-title":"Correlation Between PSA Density and Multiparametric Prostate MRI in the Diagnosis of Prostate Cancer","volume":"23","author":"Ergin","year":"2024","journal-title":"Bull. Urooncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Guo, S., Zhang, J., Jiao, J., Li, Z., Wu, P., Jing, Y., Qin, W., Wang, F., and Ma, S. (2023). Comparison of prostate volume measured by transabdominal ultrasound and MRI with the radical prostatectomy specimen volume: A retrospective observational study. BMC Urol., 23.","DOI":"10.1186\/s12894-023-01234-5"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00330-025-11837-1","article-title":"Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: A prospective feasibility study (ReIMAGINE study)","volume":"36","author":"Thorley","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_4","first-page":"381","article-title":"Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies","volume":"115","author":"Siddiqui","year":"2014","journal-title":"BJU Int."},{"key":"ref_5","first-page":"381","article-title":"Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: A novel multivariable model","volume":"115","author":"Siech","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.acra.2024.12.012","article-title":"An Automatic Deep-Radiomics Framework for Prostate Cancer Diagnosis and Stratification in Patients with Serum Prostate-Specific Antigen of 4.0\u201310.0 ng\/mL: A Multicenter Retrospective Study","volume":"32","author":"Zheng","year":"2025","journal-title":"Acad. Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1007\/s00345-023-04613-7","article-title":"Clinical value of prostate health index as an indicator for recommending magnetic resonance imaging in patients with gray-zone prostate-specific antigen level","volume":"41","author":"Song","year":"2023","journal-title":"World J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s11255-023-03692-0","article-title":"Clinical efficacy of prostate PI-RADS V2.1 score combined with serum PSA-related indicators in the detection of gray zone prostate cancer","volume":"55","author":"Lin","year":"2023","journal-title":"Int. Urol. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.21037\/tau-23-80","article-title":"Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: A prospective diagnostic study","volume":"12","author":"Wu","year":"2023","journal-title":"Transl. Androl. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.euf.2025.05.021","article-title":"Evaluation of Different National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer for Germline Genetic Testing in Localized and Locally Recurrent Prostate Cancer","volume":"11","author":"Kachanov","year":"2025","journal-title":"Eur. Urol. Focus."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.23736\/S2724-6051.24.06118-4","article-title":"Prostate cancer diagnostic pathway in men with lower urinary tract symptoms or performing opportunistic screening: The Italian Society of Urology (SIU) position paper","volume":"76","author":"Ficarra","year":"2024","journal-title":"Minerva Urol. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wang, F., Chen, T., Wang, M., Chen, H., Wang, C., Liu, P., Liu, S., Luo, J., Ma, Q., and Xu, L. (2021). Clinically significant prostate cancer (csPCa) detection with various prostate sampling schemes based on different csPCa definitions. BMC Urol., 21.","DOI":"10.1186\/s12894-021-00949-7"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chen, H., Qian, Y., Wu, Y., Shi, B., Zhou, J., Qu, F., Gu, Z., Ding, J., and Yu, Y. (2022). Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.864111"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1007\/s00261-024-04458-7","article-title":"Impact of prostate MRI image quality on diagnostic performance for clinically significant prostate cancer (csPCa)","volume":"49","author":"Cheng","year":"2024","journal-title":"Abdom. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s12672-025-03402-5","article-title":"Biproximate ellipsoid formula with transrectal ultrasound: A superior method for PSA density in gray zone prostate cancer detection","volume":"16","author":"Wang","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/pros.70036","article-title":"Prostate Volume and PSA-Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics","volume":"85","author":"Kurucz","year":"2025","journal-title":"Prostate"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2024.04.001","article-title":"The Impact of Prostate Volume on Prostate Cancer Detection: Comparing Magnetic Resonance Imaging with Transrectal Ultrasound in Biopsy-naive Men","volume":"64","author":"Ye","year":"2024","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/17434440.2020.1755257","article-title":"Use of multiparametric magnetic resonance imaging (mpMRI) in localized prostate cancer","volume":"17","author":"Wang","year":"2020","journal-title":"Expert. Rev. Med. Devices"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jama.2025.13722","article-title":"Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial","volume":"334","author":"Ng","year":"2025","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lopez-Valcarcel, M., Lopez-Campos, F., Zafra-Martin, J., Cienfuegos Belmonte, I., Subiela, J.D., Ruiz-Vico, M., Fernandez Alonso, S., Garcia Cuesta, J.A., and Counago, F. (2025). Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202506.1608.v1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1148\/radiol.212536","article-title":"Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study","volume":"305","author":"Singh","year":"2022","journal-title":"Radiology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102150","DOI":"10.1016\/j.suronc.2024.102150","article-title":"Preoperative multiparametric magnetic resonance imaging based risk stratification system for predicting biochemical recurrence after radical prostatectomy","volume":"57","author":"Akpinar","year":"2024","journal-title":"Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pantelidou, M., Caglic, I., George, A., Blyuss, O., Gnanapragasam, V.J., and Barrett, T. (2022). Evaluation of transabdominal and transperineal ultrasound-derived prostate specific antigen (PSA) density and clinical utility compared to MRI prostate volumes: A feasibility study. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0274014"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.urology.2022.09.007","article-title":"MRI vs Transrectal Ultrasound to Estimate Prostate Volume and PSAD: Impact on Prostate Cancer Detection","volume":"171","author":"Choe","year":"2023","journal-title":"Urology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12301-023-00335-9","article-title":"Diagnostic accuracy of MRI-based PSA density for detection of prostate cancer among the Thai population","volume":"29","author":"Aphinives","year":"2023","journal-title":"Afr. J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"\u00c7apkan, D.\u00dc., and \u015eahan, M.H. (Curr. Med. Imaging Former. Curr. Med. Imaging Rev., 2026). Association of Prostate Multiparametric MRI Parameters with Gleason Score: A Fusion Biopsy-Based Correlation, Curr. Med. Imaging Former. Curr. Med. Imaging Rev., in press.","DOI":"10.2174\/0115734056436931260214191215"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41391-024-00884-2","article-title":"Biopsy strategies in the era of mpMRI: A comprehensive review","volume":"28","author":"Windisch","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00330-025-11603-3","article-title":"Diagnostic accuracy of multiparametric MRI for detecting unconventional prostate cancer histology: A systematic review and meta-analysis","volume":"36","author":"Carletti","year":"2026","journal-title":"Eur. Radiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"20150039","DOI":"10.1515\/ijb-2015-0039","article-title":"Sample Size for Assessing Agreement between Two Methods of Measurement by Bland-Altman Method","volume":"12","author":"Lu","year":"2016","journal-title":"Int. J. Biostat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2214\/AJR.15.15765","article-title":"Prostate Imaging Reporting and Data System (PI-RADS), Version 2: A Critical Look","volume":"206","author":"Rosenkrantz","year":"2016","journal-title":"Am. J. Roentgenol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Aprikian, S., Luz, M., Brimo, F., Scarlata, E., Hamel, L., Cury, F.L., Tanguay, S., Aprikian, A.G., Kassouf, W., and Chevalier, S. (2019). Improving ultrasound-based prostate volume estimation. BMC Urol., 19.","DOI":"10.1186\/s12894-019-0492-2"},{"key":"ref_32","first-page":"530","article-title":"Is the Ellipsoid Formula Reliable in Prostate MRI?","volume":"49","author":"Teica","year":"2023","journal-title":"Curr. Health Sci. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5152\/dir.2020.20023","article-title":"Evaluation of prostate volume in mpMRI: Comparison of the recommendations of PI-RADS v2 and PI-RADS v2.1","volume":"27","author":"Gundogdu","year":"2021","journal-title":"Diagn. Interv. Radiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Peng, Y., Wei, C., Li, Y., Zhao, F., Liu, Y., Jiang, T., Chen, Z., Zheng, J., Fu, J., and Wang, P. (2025). Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings. BMC Urol., 25.","DOI":"10.1186\/s12894-025-01719-5"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1038\/s41598-025-95750-z","article-title":"MRI-guided biopsy reduces biochemical recurrence in prostate cancer patients undergoing radiation therapy: A single-center study from Thailand","volume":"15","author":"Mahamongkol","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s11136-018-2076-0","article-title":"Assessing test\u2013retest reliability of patient-reported outcome measures using intraclass correlation coefficients: Recommendations for selecting and documenting the analytical formula","volume":"28","author":"Qin","year":"2018","journal-title":"Qual. Life Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.euo.2020.12.004","article-title":"Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis","volume":"4","author":"Mazzone","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.euf.2017.11.010","article-title":"Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists","volume":"5","author":"Sonn","year":"2019","journal-title":"Eur. Urol. Focus."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1007\/s11255-025-04551-w","article-title":"Analysis of gray zone PSA and PSAD correlated with PIRADS v2.1 in the MRI-US fusion prostate biopsy era: A retrospective bi-centre study","volume":"57","author":"Cobangbang","year":"2025","journal-title":"Int. Urol. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.juro.2018.05.016","article-title":"Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index","volume":"200","author":"Aminsharifi","year":"2018","journal-title":"J. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.euros.2025.03.006","article-title":"Personalised Prostate Cancer Diagnosis: Evaluating Biomarker-based Approaches to Reduce Unnecessary Magnetic Resonance Imaging and Biopsy Procedures","volume":"75","author":"Soeterik","year":"2025","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.euo.2022.03.007","article-title":"A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study","volume":"5","author":"Luiting","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"W720","DOI":"10.2214\/AJR.12.9712","article-title":"Fully automated prostate segmentation on MRI: Comparison with manual segmentation methods and specimen volumes","volume":"201","author":"Turkbey","year":"2013","journal-title":"Am. J. Roentgenol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/bjr\/tqad027","article-title":"Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making","volume":"97","author":"Rajendran","year":"2024","journal-title":"Br. J. Radiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1038\/s41598-024-57337-y","article-title":"PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4\u201310 ng\/ml","volume":"14","author":"Wen","year":"2024","journal-title":"Sci. Rep."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/221\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:44:13Z","timestamp":1776336253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["curroncol33040221"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33040221","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}